# US 2014/0154218 A1 · Anti-allergic agent > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0154218 A1 - Document ID: US20140154218A1 - Status: Published application - Kind: A1 - Application number: 14/176,219 - Filed: 2014-02-10 - Published: 2014-06-05 - Earliest claimed: 2010-03-24 - Assignees: Morishita Jintan Co., Ltd. - Applicants: Morishita Jintan Co., Ltd. - Inventors: Mamiko KOHNO; Shinichi KITAMURA; Aiko SHOJO - Web page: https://patentgrep.com/patent/US20140154218A1 ## CPC - A61K 35/745: Bifidobacteria - A61K 31/715: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters - A61K 31/716: Glucans - A61P 17/00: Drugs for dermatological disorders - A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) - C08B 37/006: {Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21) ## Abstract According to the present invention, an anti-allergic agent is provided which includes a polysaccharide comprising galactose, glucose and rhamnose as constituents, or includes a microorganism belonging to a genus Bifidobacterium and extracellularly producing the polysaccharide. The anti-allergic agent of the present invention can be used in oral compositions and compositions for external application, and is suitable for use in products such as food products, pharmaceutical products, and cosmetics. ## Claims ### Claim 1 A method for treating allergic disease, comprising: administering a polysaccharide comprising galactose, glucose and rhamnose as constituents to a subject. ### Claim 2 (depends on 1) The method according to claim 1, wherein the polysaccharide comprises galactose, glucose and rhamnose in a molar ratio of 3-5:1-3:1. ### Claim 3 (depends on 2) The method according to claim 2, wherein the polysaccharide comprises the following structure: ### Claim 4 (depends on 1) The method according to claim 1, wherein the polysaccharide is obtained from a microorganism belonging to a genus Bifidobacterium. ### Claim 5 (depends on 4) The method according to claim 4, wherein the microorganism belonging to the genus Bifidobacterium is Bifidobacterium longum. ### Claim 6 (depends on 5) The method according to claim 5, wherein the Bifidobacterium longum is Bifidobacterium longum strain JBL05(NITE BP-82). ### Claim 7 (depends on 1) The method according to claim 1, wherein the polysaccharide is administered as an oral composition. ### Claim 8 (depends on 7) The method according to claim 7, wherein the polysaccharide is administered for suppressing atopic dermatitis or contact dermatitis. ### Claim 9 (depends on 1) The method according to claim 1, wherein the polysaccharide is administered as a composition for external application. ### Claim 10 (depends on 9) The method according to claim 9, wherein the polysaccharide is administered for suppressing atopic dermatitis or contact dermatitis. ### Claim 11 (depends on 2) The method according to claim 2, wherein the polysaccharide is obtained from a microorganism belonging to a genus Bifidobacterium. ### Claim 12 (depends on 3) The method according to claim 3, wherein the polysaccharide is obtained from a microorganism belonging to a genus Bifidobacterium. ### Claim 13 An anti-allergic agent comprising a microorganism, the microorganism belonging to a genus Bifidobacterium and producing an extracellular polysaccharide comprising galactose, glucose and rhamnose as constituents. ### Claim 14 (depends on 13) The anti-allergic agent according to claim 13, wherein the polysaccharide comprises galactose, glucose and rhamnose in a molar ratio of 3-5:1-3:1. ### Claim 15 (depends on 14) The anti-allergic agent according to claim 14, wherein the polysaccharide comprises the following structure: ### Claim 16 (depends on 13) The anti-allergic agent according to claim 13, wherein the microorganism is Bifidobacterium longum strain JBL05 (NITE BP-82). ### Claim 17 (depends on 13) An oral composition comprising the anti-allergic agent of claim 13. ### Claim 18 (depends on 17) The oral composition according to claim 17, for suppressing atopic dermatitis or contact dermatitis. ### Claim 19 A method for treating allergic disease, comprising: administering a microorganism belonging to a genus Bifidobacterium and producing an extracellular polysaccharide comprising galactose, glucose and rhamnose as constituents. ### Claim 20 (depends on 19) The method according to claim 19, wherein the polysaccharide comprises galactose, glucose and rhamnose in a molar ratio of 3-5:1-3:1. ### Claim 21 (depends on 20) The method according to claim 20, wherein the polysaccharide comprises the following structure: ### Claim 22 (depends on 19) The method according to claim 19, wherein the microorganism is Bifidobacterium longum strain JBL05 (NITE BP-82). ### Claim 23 (depends on 19) The method according to claim 19, wherein the microorganism is administered as an oral composition. ### Claim 24 (depends on 23) The method according to claim 23, wherein the microorganism is administered for suppressing atopic dermatitis or contact dermatitis.